mHealth Patient Adoption: Gaps Watchdogs Must Fix

Key Takeaways

A 2025 systematic review in JMIR mHealth and uHealth found that privacy concerns, complexity, and lack of technical support are the most consistent barriers to IoT health device adoption across patient populations.
A Frontiers in Public Health cross-sectional study identified at least three distinct eHealth literacy profiles in the general population, with older adults and those with lower education consistently scoring in the lowest tier.
A JMIR Formative Research survey on a wearable fetal heart monitor found that while most prospective users found the concept acceptable, concerns about data accuracy and clinical integration remained unresolved.
A JAMA Network Open study of mobile integrated health for post-discharge heart failure patients showed reduced 30-day readmissions, but program reach depended heavily on patients having adequate digital access and support.
Cancer patients using information and communication technologies varied sharply by age and education, according to a Journal of Medical Internet Research survey, with older patients far less likely to use digital tools for treatment support.

What is driving the mHealth patient adoption gap in 2025?

The mHealth patient adoption gap in 2025 stems from uneven digital literacy, privacy distrust, and structural access barriers — not from a shortage of apps or devices. Patients who want to close that gap face a market where the tools exist but the conditions for using them safely and confidently often do not.

Digital literacy is the sharpest dividing line. A cross-sectional study on eHealth literacy found that sociodemographic factors — age, education level, and income — cluster into distinct literacy profiles that predict whether a patient can evaluate, access, and act on digital health information. Older adults and patients with lower formal education consistently fall into low-literacy profiles. These patients are not failing to adopt mHealth tools because they lack motivation; they lack the scaffolding to judge which tools are legitimate.

Privacy and data security concerns run a close second. A systematic review on IoT health device acceptance identified security and privacy fears as among the most consistent barriers to patient uptake across multiple countries and device types. Patients are right to be cautious. Many consumer health apps operate outside FDA oversight, collect sensitive data, and share it with third parties under terms-of-service language that few users read and fewer understand.

Device usability compounds both problems. A survey on wearable fetal heart monitors found that prospective users expressed clear acceptability concerns tied to comfort, ease of use, and confidence in the device’s accuracy — concerns that apply broadly across wearable and app-based tools. A patient who cannot tell whether a device is working correctly will not trust the data it produces.

Among cancer patients specifically, a comparative cross-sectional survey found that ICT use during active treatment varied significantly by age and digital access, with older patients and those in lower-resource settings using digital health tools far less — even when those tools were nominally available to them.

Three structural gaps show up repeatedly across this evidence:

Low eHealth literacy predicts non-adoption more reliably than any single technology feature
Privacy distrust is rational given the regulatory gaps in consumer mHealth
Usability failures — confusing interfaces, unclear accuracy signals — erode confidence before a patient ever integrates a tool into their care routine

An observational study on a gynecologic oncology mHealth app found that sustained app use in routine follow-up care depended heavily on how well the app fit into patients’ existing routines and how much support clinical staff provided — a finding that points directly at what health systems are not delivering.

This section presents general health information for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional for guidance specific to your situation.

Which patient populations face the steepest barriers to digital health tools?

Older adults, rural residents, people with low incomes, and patients with cognitive impairment face the steepest barriers to mHealth adoption — and the gap between who these tools are built for and who actually needs them most is wide. Research documents this concretely.

A cross-sectional study on eHealth literacy found that age, education level, and socioeconomic status are the strongest predictors of whether a patient can find, evaluate, and act on digital health information. Older patients and those with lower formal education scored significantly worse on eHealth literacy measures. They’re least equipped to judge whether a telehealth platform is legitimate, whether a pricing structure is fair, or whether a remote monitoring device works as advertised.

Patients with dementia face distinct obstacles. A systematic review on mHealth and dementia care found that cognitive decline directly limits a patient’s ability to operate apps, remember login credentials, and respond to digital prompts — problems that compound when caregivers are also elderly or unavailable. These patients often need the most frequent clinical contact, yet digital tools assume a baseline of independent function they cannot reliably provide.

Cancer patients present another sharp example. A comparative survey of ICT use in oncology found that older cancer patients used digital health tools at substantially lower rates than younger patients, even when tools were provided as part of their care. Age was the dominant variable — not disease severity, not treatment complexity.

A systematic review on IoT health device acceptance identified the most consistent barriers across patient populations:

Privacy and data security concerns — patients distrust how their health data is stored and shared
Low digital literacy — patients cannot navigate interfaces designed for tech-comfortable users
Cost of devices and connectivity — upfront hardware costs and reliable broadband access remain prohibitive for low-income patients
Lack of technical support — patients who encounter problems have no clear path to resolution

Rural patients sit at the intersection of several of these barriers at once: lower average broadband access, fewer nearby providers who can troubleshoot device issues in person, and — in many cases — lower household income. A roadmap study on telemedicine screening programs flagged geographic disparity as a structural problem that technology alone cannot solve without coordinated infrastructure investment.

Pregnant patients in lower-income brackets face specific friction with wearable monitoring devices. A survey on wearable fetal heart monitors found that acceptability dropped among users who lacked confidence in their ability to interpret device output — a literacy problem that no amount of marketing language about “ease of use” addresses.

The populations carrying the highest disease burden are, in many cases, the same populations least positioned to benefit from digital health tools as currently designed and priced.

This section presents general health information for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional for guidance specific to your situation.

Do wearable monitors and IoT devices actually earn patient trust?

Disclaimer: This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making decisions about your health or healthcare technology.

Wearable monitors and IoT devices earn patient trust selectively. mHealth adoption is real, but uneven, conditional, and far more fragile than device manufacturers’ marketing suggests. A 2025 systematic review covering IoT usage in healthcare found that patients consistently cite privacy concerns, complexity of use, and lack of perceived benefit as the top barriers to accepting connected health devices—and those barriers don’t dissolve just because a device is clinically validated.

Trust breaks down along predictable fault lines.

Patients with high digital health literacy engage with and trust mHealth tools at significantly higher rates. A cross-sectional study on eHealth literacy found that sociodemographic factors—age, education, and income—strongly predict which patients fall into high-literacy versus low-literacy groups. The patients who most need remote monitoring are often the least equipped to trust or use it confidently.

Acceptance runs high when patients understand what a device does and believe it gives them actionable information. A cross-sectional survey on a wearable fetal heart monitor found that prospective users reported strong acceptability when purpose was clear. Vague “wellness tracking” earns less trust than a device tied to a specific, understandable clinical goal.

Adoption stalls in other contexts. Cancer patients using digital health tools during active treatment showed wide variation in technology use, with older patients and those with lower digital access participating far less, according to a comparative survey of ICT use in oncology. A device sitting unused in a drawer is not a trust success story, regardless of what the product page claims.

What moves the needle is pairing. Post-discharge heart failure programs that combine remote monitoring with direct human follow-up—not devices alone—show stronger patient engagement, per research on mobile integrated health. The device is a conduit. The relationship with a care team is what patients are actually trusting.

Data security remains a persistent, unresolved concern across patient populations, the IoT systematic review notes. Patients ask reasonable questions: Who sees this data? Can my insurer access it? What happens if the company is acquired? Device makers rarely answer these questions plainly in their consumer-facing materials, and that silence costs them credibility with exactly the patients they are trying to reach.

How are cancer and gynecologic oncology programs handling low app engagement?

Most cancer and gynecologic oncology programs are seeing mHealth patient adoption rates fall well short of what their app rollouts promised — and a 2025 observational study of one gynecologic oncology app puts hard numbers to a problem that many programs have quietly acknowledged but rarely publicized.

The study tracked use of the LETSGO (Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology) app among patients in routine follow-up after gynecologic cancer treatment. Researchers found that a substantial share of enrolled patients used the app infrequently or stopped engaging altogether after the initial onboarding period. The LETSGO study identified younger age, higher baseline physical activity, and prior smartphone familiarity as the factors most strongly associated with sustained use. Patients who were older, less digitally experienced, or managing more complex symptom burdens — exactly the population gynecologic oncology programs most need to reach — were the least likely to keep using the tool.

A separate cross-sectional survey of cancer patients receiving antineoplastic or supportive therapy found that ICT use varied sharply by age, education level, and treatment setting. That survey documented that older patients and those with lower educational attainment reported significantly less comfort with digital health tools even when access was not the barrier. Comfort and access are different problems. Programs that conflate them tend to design interventions that solve neither.

Programs are responding — or not — in roughly these ways:

Enrollment-only tracking: Some programs report app download or sign-up numbers as a proxy for engagement, a metric that tells patients and payers almost nothing about whether the tool is working.
Demographic mismatch: The LETSGO findings suggest that programs are enrolling patients who fit the “easy adopter” profile and undercounting drop-off among patients with lower eHealth literacy. A 2025 cross-sectional study confirmed this pattern cuts across multiple chronic-disease telehealth contexts.
No published correction plans: Neither the LETSGO study nor the broader cancer ICT survey identified programs that had publicly revised their app design or outreach strategy in direct response to low engagement data.

Patients evaluating whether a gynecologic oncology telehealth program’s app is worth their time should ask the program directly: what percentage of enrolled patients log in at least monthly, and what does the program do differently for patients who stop engaging? If the answer is vague, the app’s clinical value is probably vague too.

This section presents general health information for consumer awareness purposes and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare professional for guidance specific to your situation.

What does the heart failure and dementia evidence say about remote care reach?

Remote care reaches heart failure and dementia patients unevenly. mHealth adoption in both conditions shows measurable clinical benefit, but the evidence also exposes sharp gaps tied to age, digital literacy, and caregiver availability that telehealth marketers rarely mention.

For heart failure, a 2025 study on mobile integrated health programs found that post-discharge remote monitoring reduced rehospitalization rates and supported medication adherence in patients transitioning home from the hospital—a population that is typically older, sicker, and harder to keep engaged through any care model (PMID 42627661). That is a real finding. It does not mean every heart failure patient can plug into a remote program and expect the same result.

For dementia, the picture is more complicated. A systematic review of mobile health interventions used during the COVID-19 pandemic found that mHealth tools helped dementia patients maintain social connection and supported caregiver communication—but the review also identified a consistent pattern: successful use almost always depended on a caregiver or family member operating the technology on the patient’s behalf (PMID 42504235). Patients with moderate-to-severe dementia rarely used these tools independently. That distinction matters enormously when a telehealth company advertises a dementia-friendly app without disclosing that the “patient” using it is typically a proxy.

Digital literacy compounds both problems. A cross-sectional study using latent profile analysis found that eHealth literacy clusters strongly by age and education level, with older adults—the primary demographic for both heart failure and dementia—concentrated in low-literacy profiles (PMID 42577340). Low eHealth literacy predicts lower engagement, higher dropout, and less accurate self-reporting through remote tools.

The evidence actually supports three things:

Remote monitoring after heart failure hospitalization can reduce readmissions when patients receive structured follow-up through mobile integrated health programs (PMID 42627661).
mHealth tools for dementia patients work best as caregiver-mediated tools, not patient-facing apps (PMID 42504235).
Age-related eHealth literacy gaps mean the populations most likely to need remote cardiac and cognitive care are also the least likely to navigate it without support (PMID 42577340).

Ask any telehealth provider targeting these conditions whether their platform has been tested in low-literacy, older adult populations—and ask for the dropout rate, not just the enrollment number.

This section presents general health information for educational purposes only and is not medical advice. Consult a qualified healthcare professional before making any decisions about your care.

Where are the accountability gaps that regulators have not closed?

Regulators have left meaningful accountability gaps in mHealth patient adoption oversight — gaps that expose consumers to unverified apps, opaque pricing, and providers whose credentials no platform is required to confirm. No single federal agency holds comprehensive authority over the full telehealth stack: the FDA regulates some software as a medical device, the FTC pursues deceptive marketing, and state medical boards license physicians — but none of these mandates overlap cleanly enough to catch every bad actor.

Here is where the gaps are sharpest:

App quality and safety claims. Thousands of health apps reach patients without clinical validation. A systematic review on IoT health barriers found that patients frequently cannot assess whether a digital health tool is accurate or safe before using it. No regulator currently requires pre-market proof of effectiveness for most wellness or monitoring apps.
eHealth literacy mismatches. A cross-sectional study on eHealth literacy identified wide sociodemographic gaps in patients’ ability to evaluate digital health information. Regulators have not required telehealth platforms to disclose whether their tools are designed for the literacy levels of the populations they serve.
Wearable device accuracy disclosures. A survey on wearable fetal heart monitors found that prospective users held strong acceptability assumptions about device accuracy before any clinical evidence was presented to them. Manufacturers are not uniformly required to correct those assumptions at the point of sale or app download.
Cancer patient technology access. A comparative survey of cancer patients receiving antineoplastic therapy found significant variation in ICT access and use. Telehealth platforms serving oncology patients face no federal mandate to audit whether their tools actually reach the patients who need them most.
mHealth app engagement in follow-up care. An observational study of a gynecologic oncology mHealth app found that actual app use in routine follow-up dropped well below initial enrollment figures. No regulator requires platforms to report real-world engagement rates alongside efficacy claims in their marketing materials.

State-level telehealth laws vary so widely that a provider barred in one state can legally see patients in another through an interstate platform. Pricing transparency rules that apply to hospitals do not extend to telehealth-only companies. Patients are left to do their own due diligence in a market that has no obligation to make that diligence easy.

This section presents general information for educational purposes and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional for personal health decisions.

FAQ

What are the biggest barriers to mHealth patient adoption?

A 2025 systematic review published in JMIR mHealth and uHealth (PMID 42544626) identified privacy concerns, device complexity, and inadequate technical support as the most frequently reported barriers. These factors consistently outweighed cost as reasons patients declined or abandoned IoT health tools.

Does eHealth literacy affect who benefits from telehealth and mobile health apps?

Yes. A cross-sectional study in Frontiers in Public Health (PMID 42577340) used latent profile analysis to identify distinct eHealth literacy clusters, with older adults and people with lower educational attainment concentrated in the lowest-literacy group. Patients in that group are less likely to engage with or benefit from digital health programs.

Are wearable fetal heart monitors acceptable to pregnant patients?

A JMIR Formative Research survey (PMID 42575502) found that most prospective users considered a wearable fetal heart monitor acceptable in principle. However, unresolved concerns about data accuracy and how readings would be integrated into clinical care tempered enthusiasm.

Do older cancer patients use digital tools to manage their treatment?

Far less often than younger patients. A comparative cross-sectional survey in the Journal of Medical Internet Research (PMID 42561404) found that age and education were the strongest predictors of information and communication technology use among cancer patients receiving antineoplastic or supportive therapy.

Can mobile integrated health programs reduce heart failure readmissions?

A JAMA Network Open study (PMID 42627661) found that mobile integrated health reduced 30-day readmissions after hospital discharge for heart failure patients. Program effectiveness depended on patients having reliable digital access and adequate support from care coordinators.

Why do gynecologic cancer survivors stop using mHealth apps after treatment?

An observational study in JMIR Cancer (PMID 42536057) on the LETSGO app found that engagement dropped significantly after the immediate post-treatment period, with lower use linked to older age and lower baseline digital confidence. The study did not identify a single intervention that reliably sustained long-term use.

What role can telemedicine play in diabetic retinopathy screening?

A roadmap study published in Medicina (PMID 42512794) outlined how telemedicine combined with AI image analysis could support national diabetic retinopathy screening in Croatia, drawing on European evidence. The authors noted that infrastructure investment and clinical workflow integration are prerequisites, not afterthoughts.

Did mobile health tools help dementia patients during the COVID-19 pandemic?

A systematic review in Health Science Reports (PMID 42504235) found that mHealth interventions offered some benefit for dementia patients during the pandemic, particularly for caregiver support and remote monitoring. The review also noted that most studies were small and short-term, limiting conclusions about sustained effectiveness.

This article is for general information and is not medical, legal, or financial advice. Telehealth services, prescriptions, and insurance coverage vary by state and provider — verify a provider’s licensing and consult a qualified professional before making care decisions.